Schizophrenia - Pipeline Review, Q4 2010

Schizophrenia - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Schizophrenia Pipeline Review, Q4 2010”, provides an overview of the Schizophrenia therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Schizophrenia. “Schizophrenia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Schizophrenia.
- A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Schizophrenia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Schizophrenia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Schizophrenia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Schizophrenia Overview
Therapeutics Development
An Overview of Pipeline Products for Schizophrenia
Schizophrenia Therapeutics under Development by Companies
Schizophrenia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Schizophrenia Therapeutics Development
Johnson & Johnson
Abbott Laboratories
NsGene A/S
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Taisho Pharmaceutical Co., Ltd.
ZARS Pharma, Inc.
BioLineRx, Ltd.
Avineuro Pharmaceuticals, Inc.
Alexza Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc.
Novartis AG
EnVivo Pharmaceuticals
Astellas Pharma Inc.
Cephalon, Inc.
Daewoong Pharmaceutical Co., Ltd.
Gedeon Richter Plc.
H Lundbeck A/S
Orion Corporation
Pfizer Inc.
Evotec Aktiengesellschaft
GW Pharmaceuticals plc
IntelGenx Technologies Corp.
Ligand Pharmaceuticals Incorporated
NeuroSearch A/S
NPS Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc.
Alfred Health Victoria
Repligen Corporation
SYGNIS Pharma AG
Minster Pharmaceuticals plc
Biotie Therapies Corp.
Suven Life Sciences Ltd.
Newron Pharmaceuticals S.p.A.
Mithridion, Inc.
Eusa Pharma (Europe) Ltd.
Synosia Therapeutics AG
Halcygen Pharmaceuticals Limited
Domain Therapeutics
Critical Pharmaceuticals Limited
BioQuest Innovations Inc.
Fabre-Kramer Pharmaceuticals, Inc.
Oakwood Laboratories L.L.C.
Xytis Inc.
Omeros Corporation
Intra-Cellular Therapies, Inc.
Targacept, Inc.
Galenea Corp.
Marinus Pharmaceuticals, Inc.
M's Science Corporation
BrainCells Inc.
KemPharm, Inc.
SK Bio-Pharmaceuticals
Research Foundation for Mental Hygiene, Inc
Naurex, Inc.
Dong Wha Pharma Co., Ltd.
Universities/Institutes Involved in Schizophrenia Therapeutics Development
Schizophrenia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZ-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cariprazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Latuda - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nuvigil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Amantadine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atomoxetine + Clozapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bexarotene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Buspirone + Risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-Cycloserine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-Serine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-serine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EGb-761 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ethyl-Eicosapentaenoic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabitril - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glycine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IM Risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Intravenous immunoglobulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levosulpiride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olanzapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olanzapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olanzapine + Clozapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omega-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxcarbazepine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Perphenazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregnenolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Quetiapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Quetiapine + Risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Targretin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Targretin + Fenretinide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tropisetron + Risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valnoctamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Varenicline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Schizophrenia - Featured News
Dec 07, 2010: Alexza Pharmaceuticals Provides Regulatory Update For AZ-004
Nov 30, 2010: Cyrenaic Reports Improvement Of Negative Symptoms And Cognition In Schizophrenia Patients Treated With CYR-101
Nov 02, 2010: Latuda (lurasidone HCl) Significantly Reduced Symptoms Of Schizophrenia In New Clinical Study
Oct 28, 2010: FDA Approves Once-Daily Latuda (lurasidone HCl) For The Treatment Of Patients With Schizophrenia
Oct 11, 2010: Alexza Receives Complete Response Letter For AZ-004 NDA
Oct 05, 2010: Otsuka Reports Phase III Aripiprazole Intramuscular Depot Trial Interim Analysis Reveals Efficacy Criteria Met
Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program
Jul 29, 2010: Intra-Cellular Therapies Successfully Completes Phase Ib/II Study Of ITI-007 In Patients With Schizophrenia
Jun 02, 2010: Cephalon Provides Clinical Update On Phase II Study Of NUVIGIL As Adjunctive Therapy In Adults With Schizophrenia
May 26, 2010: Alexza Presents Additional Phase III Analyses and Phase I Cardiovascular Safety Data Of Staccato Loxapine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer